Person:
KORTEN, VOLKAN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KORTEN

First Name

VOLKAN

Name

Filters

2007 - 20082
Reset filters

Settings

Subject: BETA-LACTAMASES ×

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Susceptibility of bacterial isolates from Turkey - A report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program
    (TAYLOR & FRANCIS LTD, 2007) KORTEN, VOLKAN; Eraksoy, H.; Basustaoglu, A.; Korten, V.; Kurt, H.; Ozturk, R.; Ulusoy, S.; Yaman, A.; Yuce, A.; Zarakolu, P.
    The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum P-lactamase (ESBL) producers. Piperacillin/tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens.
  • Thumbnail Image
    PublicationOpen Access
    Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites
    (MICROBIOLOGY SOC, 2008-12-01) KORTEN, VOLKAN; Gur, Deniz; Korten, Volken; Unal, Serhat; Deshpande, Lalitagauri M.; Castanheira, Mariana
    A significant increase in carbapenem-resistance rates among Acinetobacter baumannii isolates collected in two Turkish medical centres was detected in the 2000-2006 period (20-60%) by the SENTRY Antimicrobial Surveillance Program. Carbapenem-resistant strains from 2006 were evaluated for the presence of encoding genes and epidemic clonality. OXA-58-like and OXA-23-like carbapenemase-producing strains were detected in both medical institutions. Seventeen out of 18 strains from Ankara were positive for bla(OXA-58) primers and belonged to the same clone, whilst 26 isolates (25 from Istanbul and one from Ankara) harboured bla(OXA-23)-like genes and showed identical or similar PFGE patterns. Isolates producing OXA-23-like carbapenemases were more resistant than OXA-58-like carbapenemase producers to non-carbapenem antimicrobial agents. Carbapenem resistance in these institutions was observed to be largely driven by the dissemination of clones producing OXA-type carbapenemases.